文献速递抗菌药物管理

抗菌药物经济学:耐药加剧、研发管线萎缩及社会影响

Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
PubMed 文献 · Pharmacotherapy · 2016-12-27

本文综述了抗菌药物耐药性增长与研发管线萎缩的现状,指出自1980年代至2000年代初新抗菌药物批准下降90%,科学、监管和经济障碍导致企业退出研发。文章讨论了公私合作、报销改革和市场独占期等激励措施,强调混合激励模式、全球协调和抗菌药物管理平衡定价与用量对重振研发管线的重要性。

要点

  • 耐药性增长与研发管线萎缩导致后抗生素时代风险。
  • 1980年代至2000年代初新抗菌药物批准下降90%。
  • 需混合激励模式、全球协调和抗菌药物管理以重振研发。

核心结论

  • 耐药性增长和研发管线萎缩导致后抗生素时代,需多维度激励措施重振抗菌药物研发。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • 自1940年代黄金时代后抗菌药物研发势头丧失,1980年代至2000年代初新抗菌药物批准下降90%,且新 novel 类别发现极少。

临床怎么用

  • 临床应关注抗菌药物管理,平衡药物定价、用量与合理使用,以支持研发可持续性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Growing antimicrobial resistance and a dwindling antibiotic pipeline have resulted in an emerging postantibiotic era, as patients are now dying from bacterial infections that were once treatable. The fast-paced "Golden Age" of antibiotic development that started in the 1940s has lost momentum; from the 1980s to the early 2000s, there was a 90% decline in the approval of new antibiotics as well as the discovery of few new novel classes. Many companies have shifted away from development due to scientific, regulatory, and economic hurdles that proved antibiotic development to be less attractive compared with more lucrative therapeutic areas. National and global efforts are focusing attention toward potential solutions for reinvigorating the antibiotic pipeline and include "push" incentives such as public-private partnerships and "pull" incentives such as reimbursement reform and market exclusivity. Hybrid models of incentives, global coordination among stakeholders, and the appropriate balance of antibiotic pricing, volume of drug used, and proper antimicrobial stewardship are key to maximizing efforts toward drug development to ensure access to patients in need of these therapies.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Luepke KH, Suda KJ, Boucher H, et al. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2016. PMID: 27859453. doi:10.1002/phar.1868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。